White Pine Capital LLC Boosts Holdings in NeoGenomics, Inc. $NEO

White Pine Capital LLC grew its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 394.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,822 shares of the medical research company’s stock after purchasing an additional 110,735 shares during the quarter. White Pine Capital LLC’s holdings in NeoGenomics were worth $1,072,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of NEO. Royal Bank of Canada lifted its stake in NeoGenomics by 51.2% in the 1st quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock valued at $532,000 after buying an additional 18,966 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of NeoGenomics in the first quarter worth approximately $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of NeoGenomics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock worth $719,000 after purchasing an additional 3,254 shares in the last quarter. Intech Investment Management LLC lifted its holdings in NeoGenomics by 19.7% in the 1st quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock valued at $1,441,000 after purchasing an additional 24,965 shares in the last quarter. Finally, CWM LLC boosted its stake in NeoGenomics by 118.9% during the 2nd quarter. CWM LLC now owns 13,787 shares of the medical research company’s stock worth $101,000 after purchasing an additional 7,488 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NEO shares. UBS Group reissued a “hold” rating on shares of NeoGenomics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Leerink Partners set a $14.00 price target on NeoGenomics in a research report on Tuesday, October 28th. Needham & Company LLC raised their target price on NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $11.57.

Insider Buying and Selling at NeoGenomics

In related news, COO Warren Stone sold 22,128 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. This trade represents a 15.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Alicia C. Olivo sold 20,916 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total transaction of $250,992.00. Following the completion of the sale, the executive vice president directly owned 31,083 shares of the company’s stock, valued at approximately $372,996. This trade represents a 40.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.40% of the company’s stock.

NeoGenomics Trading Down 1.2%

NASDAQ:NEO opened at $9.89 on Friday. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $13.74. The stock has a market cap of $1.28 billion, a P/E ratio of -11.77 and a beta of 1.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 4.26. The stock has a 50-day simple moving average of $12.06 and a 200-day simple moving average of $10.14.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $190.17 million for the quarter, compared to analyst estimates of $188.25 million. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $0.04 EPS. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.